sirolimus and Skin-Ulcer

sirolimus has been researched along with Skin-Ulcer* in 3 studies

Reviews

1 review(s) available for sirolimus and Skin-Ulcer

ArticleYear
Generalized, pruritic, ulcerating maculopapular rash necessitating cessation of sirolimus in a liver transplantation patient.
    Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, 2005, Volume: 11, Issue:8

    The use of sirolimus as an alternative to calcineurin antagonists has enabled the continuation of immunosuppression in patients with renal impairment with preservation of kidney function. Sirolimus is generally well tolerated, with the main causes of cessation of therapy related to its effect on blood lipid profile as well as leukopenia and thrombocytopenia. We report a case of a debilitating ulcerating maculopapular rash necessitating cessation of the drug in a liver transplantation patient. A 56-year-old Caucasian liver transplantation patient presented with a diffuse, debilitating rash attributed to sirolimus use. This ultimately necessitated cessation of the immunosuppressant with subsequent resolution of her symptoms. From a review of the current literature, this is a highly unusual adverse reaction to sirolimus.

    Topics: Drug Administration Schedule; Drug Eruptions; Female; Humans; Immunosuppressive Agents; Liver Transplantation; Middle Aged; Pruritus; Sirolimus; Skin Ulcer

2005

Other Studies

2 other study(ies) available for sirolimus and Skin-Ulcer

ArticleYear
[Delayed wound healing during therapy of cutaneous graft-versus-host disease with everolimus].
    Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete, 2014, Volume: 65, Issue:6

    Graft-versus-host-disease (GvHD) is despite improvement in transplantation medicine the major cause for morbidity and mortality after allogeneic stem cell transplantation. We describe a patient with chronic cutaneous GvHD who developed massive skin ulcerations after changing the immunosuppressive therapy to a mammalian target of rapamycin (mTOR)-inhibitor.

    Topics: Everolimus; Graft vs Host Disease; Humans; Immunosuppressive Agents; Male; Middle Aged; Sirolimus; Skin Ulcer; Stem Cell Transplantation; Treatment Outcome

2014
Prolonged response using gefitinib followed by sirolimus for advanced cutaneous squamous cell carcinoma.
    Journal of the American Academy of Dermatology, 2012, Volume: 67, Issue:5

    Topics: Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Drug Therapy, Combination; ErbB Receptors; Gefitinib; Humans; Lymphatic Metastasis; Male; Quinazolines; Sirolimus; Skin Neoplasms; Skin Ulcer; TOR Serine-Threonine Kinases

2012